State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3

Caro, 2012, Modeling good research practices - overview: A report of the ISPOR-SMDM modeling good research practices task force-1, Value Health, 15, 796, 10.1016/j.jval.2012.06.012 Roberts, 2012, Conceptualizing a model: A report of the ISPOR-SMDM modeling good research practices task force-2, Value Health, 15, 804, 10.1016/j.jval.2012.06.016 Karnon, 2012, Modeling using discrete event simulation: A report of the ISPOR-SMDM modeling good research practices task force-4, Value Health, 15, 821, 10.1016/j.jval.2012.04.013 Pitman, 2012, Dynamic transmission modeling: A report of the ISPOR-SMDM modeling good research practices task force-5, Value Health, 15, 828, 10.1016/j.jval.2012.06.011 Briggs, 2012, Model parameter estimation and uncertainty: A report of the ISPOR-SMDM modeling good research practices task force-6, Value Health, 15, 835, 10.1016/j.jval.2012.04.014 Eddy, 2012, Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task force-7, Value Health, 15, 843, 10.1016/j.jval.2012.04.012 Beck, 1983, The Markov process in medical prognosis, Med Decis Making, 3, 419, 10.1177/0272989X8300300403 Sonnenberg, 1993, Markov models in medical decision making: a practical guide, Med Decis Making, 13, 322, 10.1177/0272989X9301300409 Spielauer, 2007, Dynamic microsimulation of health care demand, health care finance and the economic impact of health behaviours: survey and review, Int J Microsimuation, 1, 35, 10.34196/ijm.00005 Groot Koerkamp, 2010, Uncertainty and patient heterogeneity in medical decision models, Med Decis Making, 30, 194, 10.1177/0272989X09342277 Weinstein, 2006, Recent developments in decision-analytic modelling for economic evaluation, Pharmacoeconomics, 24, 1043, 10.2165/00019053-200624110-00002 Hunink, 2001 Caro, 2005, Pharmacoeconomic analysis using discrete event simulation, Pharmacoeconomics, 23, 323, 10.2165/00019053-200523040-00003 Siebert, 2003, When should decision-analytic modeling be used in the economic evaluation of health care?, Eur J Health Econom, 4, 143, 10.1007/s10198-003-0205-2 Col, 1997, Patient-specific decisions about hormone replacement therapy in postmenopausal women, JAMA, 277, 1140, 10.1001/jama.1997.03540380054031 Eddy, 1980 Russel, 1994 Grill, 2005, Comparing the clinical effectiveness of different new-born hearing screening strategies: a decision analysis, BMC Public Health, 5, 12, 10.1186/1471-2458-5-12 Gutierrez de Mesa, 2007, Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children, Mol Diag Ther, 11, 313, 10.1007/BF03256252 Meckley, 2010, A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing, Pharmacoeconomics, 28, 61, 10.2165/11318240-000000000-00000 Rogowski, 2009, The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study, Med Decis Making, 29, 224, 10.1177/0272989X08327112 Goldie, 2006, Cost-effectiveness of cervical cancer screening, Vaccine, 24, S164, 10.1016/j.vaccine.2006.05.114 Lee, 2010, Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers, Radiology, 254, 793, 10.1148/radiol.09091086 Sroczynski, 2011, Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis, Eur J Cancer, 47, 1633, 10.1016/j.ejca.2011.03.006 Zauber, 2008, Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force, Ann Intern Med, 149, 659, 10.7326/0003-4819-149-9-200811040-00244 Sanders, 2005, Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy, N Engl J Med, 352, 570, 10.1056/NEJMsa042657 Sanders, 2008, Cost effectiveness of HIV screening in patients older than 55 years of age, Ann Intern Med, 148, 889, 10.7326/0003-4819-148-12-200806170-00002 Trikalinos, 2009, Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations, Med Decis Making, 29, E22, 10.1177/0272989X09345022 Gould, 2003, Cost effectiveness of alternative management strategies for patients with solitary pulmonary nodules, Ann Intern Med, 138, 724, 10.7326/0003-4819-138-9-200305060-00009 Hunink, 1999, Noninvasive imaging for the diagnosis of coronary artery disease: focusing the development of new diagnostic technology, Ann Intern Med, 131, 673, 10.7326/0003-4819-131-9-199911020-00008 Cohen, 2004, Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial, Circulation, 110, 508, 10.1161/01.CIR.0000136821.99814.43 Sanders, 2005, Cost effectiveness of the implantable cardioverter defibrillator (ICD) in primary prevention of sudden death, N Engl J Med, 353, 1471, 10.1056/NEJMsa051989 Siebert, 2005, Int J Tech Assess Health Care, 21, 55, 10.1017/S0266462305050075 Freedberg, 1998, The cost-effectiveness of preventing AIDS-related opportunistic infections, JAMA, 279, 130, 10.1001/jama.279.2.130 Bentley, 2009, Effects of categorizing continuous variables in decision-analytic models, Med Decis Making, 29, 549, 10.1177/0272989X09340238 Lee, 2008, Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging–Markov Monte Carlo decision analysis, Radiology, 246, 763, 10.1148/radiol.2463070224 Clarke, 2004, A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model, Diabetologia, 47, 1747, 10.1007/s00125-004-1527-z Robins, 2004, Estimations of the effects of multiple interventions, Vol. 1, 2191 Puterman, 1994 Alagoz, 2010, Markov decision processes: a tool for sequential decision making under uncertainty, Med Decis Making, 30, 474, 10.1177/0272989X09353194 Dewilde, 2004, The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer, Med Decis Making, 24, 486, 10.1177/0272989X04268953 Lieu, 1997, Projected cost-effectiveness of primary angioplasty for acute myocardial infarction, J Am Coll Cardiol, 30, 1741, 10.1016/S0735-1097(97)00391-4 Berrington de Gonzalez, 2011, Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis, AJR Am J Roentgenol, 196, 816, 10.2214/AJR.10.4907 Kuntz, 2002, Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias, Med Decis Making, 22, 218, 10.1177/02789X02022003004 Zaric, 2003, The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis, Med Decis Making, 23, 379, 10.1177/0272989X03256883 Sonnenberg, 1994, Toward a peer review process for medical decision analysis models, Med Care, 32, JS52 Owens, 2010, Grading the strength of a body of evidence when comparing medical interventions – AHRQ and the effective health care program, J Clin Epidemiol, 63, 513, 10.1016/j.jclinepi.2009.03.009 Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011 Balshem, 2011, GRADE guidelines, 3: rating the quality of evidence, J Epidemiol, 64, 401, 10.1016/j.jclinepi.2010.07.015 Miller, 1994, Determining transition probabilities: confusion and suggestions, Med Decis Making, 14, 52, 10.1177/0272989X9401400107 Kuntz, 1995, Life expectancy biases in clinical decision modeling, Med Decis Making, 15, 158, 10.1177/0272989X9501500209 Cox, 2009, Value Health, 12, 1053, 10.1111/j.1524-4733.2009.00601.x Johnson, 2009, Value Health, 12, 1062, 10.1111/j.1524-4733.2009.00602.x Kuntz, 2001, Modelling in economic evaluation Stout, 2008, Keeping the noise down: common random numbers for disease simulation modeling, Health Care Manage Sci, 11, 399, 10.1007/s10729-008-9067-6